- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ADAPTOGENICS HEALTH Aktie jetzt für 0€ handeln | |||||
| 02.05. | Adaptogenics Health Corp: Adaptogenics Health appoints Franco CEO, starts review | 1 | Stockwatch | ||
| 01.05. | Adaptogenics Health Corp.: Adaptogenics Health Corp. Announces Strategic Review of Health & Wellness Opportunities and Management Changes | 2.605 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - May 1, 2026) - Adaptogenics Health Corp. (CSE: ADPT) ("Adaptogenics", the "Company") announces that its board of directors has initiated a strategic... ► Artikel lesen |
2 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 47,040 | +2,19 % | Bayer Aktie in Gefahr - droht erneuter Absturz? | Die Bayer Aktie hat sich aus einer schwierigen Lage zurückgekämpft. Anfang Juni war der Kurs noch knapp unter 33 Euro gefallen, inzwischen hat er sich klar erholt und sogar die 200-Tage-Linie bei 35... ► Artikel lesen | |
| UNIVERSE PHARMACEUTICALS | 12,000 | -1,48 % | Morning Market Movers: Universe Pharmaceuticals, Decoy Therapeutics, Comcast, Larimar Therapeutics See Big Swings | PHILADELPHIA (dpa-AFX) - At 7:40 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| MERCK KGAA | 146,70 | +0,20 % | DZ BANK stuft MERCK KGAA auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat die Einstufung für Merck KGaA auf "Kaufen" mit einem fairen Wert von 153 Euro belassen. Das Thema Künstliche Intelligenz (KI) sei für den Life-Science-Zuliefersektor... ► Artikel lesen | |
| NOVO NORDISK | 42,620 | +0,82 % | Novo Nordisk-Aktie: Bricht sie jetzt aus? | Die Aktie von Novo Nordisk steht nach einer längeren Schwächephase erneut im Fokus und zeigt technische Ausbruchstendenzen. Trotz operativer Herausforderungen und eines deutlichen Kursrückgangs übr... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 16,920 | +0,06 % | Generate:Biomedicines: Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update | SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 36,720 | -0,03 % | Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO (miltefosine) | IMPAVIDO is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania speciesLeishmaniasis is a rare but potentially life-threatening... ► Artikel lesen | |
| LB PHARMACEUTICALS | 32,660 | +0,06 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update | Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression Published results from the Phase 2 NOVA-1... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,170 | +0,24 % | Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last? | ||
| KARDIGAN | 25,830 | -0,27 % | How Kardigan spun deal leftovers into a $400M IPO | ||
| BRIGHT MINDS BIOSCIENCES | 69,40 | +0,32 % | Bright Minds Biosciences Announces Closing of US$175 Million Public Offering | NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945... ► Artikel lesen | |
| ATRIUM THERAPEUTICS | 13,650 | 0,00 % | Atrium Therapeutics Reports First Quarter 2026 Financial Results | SAN DIEGO, May 14, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 14,310 | -1,04 % | Kazia Therapeutics Limited: Kazia Therapeutics Appoints James Levine as Chief Financial Officer | SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company... ► Artikel lesen | |
| GRACE THERAPEUTICS | 2,300 | 0,00 % | Grace Therapeutics, Inc.: Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update | Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences Company Continues Disciplined... ► Artikel lesen | |
| ONKURE THERAPEUTICS | 4,500 | 0,00 % | OnKure Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| SEAPORT THERAPEUTICS | 22,500 | -0,09 % | Seaport Therapeutics Prices Upsized IPO Of 14.16 Mln Shares At $18 Each | WASHINGTON (dpa-AFX) - Seaport Therapeutics, Inc. (SPTX) said it has priced its upsized initial public offering of 14.16 shares at $18 per share, at the top of the target range. The company... ► Artikel lesen |
Das Unternehmen ADAPTOGENICS HEALTH CORP kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADAPTOGENICS HEALTH CORP finden Sie auf Wallstreet Online.